It is too early to comment. The field of gene therapy is still evolving. Gene therapy is relatively new and there’s still a lot about it that we do not know. Exactly how successful gene therapy will be is still uncertain.
There are still some issues that need to be addressed.
Targeting the gene to the correct cells is crucial. Delivering the gene to the wrong tissue could cause health problems for the patient. Next is the immune response. The gene-delivery vectors must be able to avoid the body's natural surveillance system. An unwelcome immune response would be detrimental or even cause death.
Ideally, when a gene is introduced, it must become a permanent part of the target cell's genome, usually by integrating into the cell's own DNA. What if the introduced gene integrates in an inappropriate location, disrupting another gene?
A good gene therapy is the one that is lasting, meaning it should continue to work for the rest of the patient's life. Then only one can say that gene therapy is lifesaving. But there is another issue of cost. All may not be able to afford this treatment. So, with limited number of patients, how is the pharmaceutical industry going to benefit? It would also be unfair not to extend this therapy to those who cannot afford.
So, a lot more work needs to be done to make gene therapy safe and affordable.